Phase I trial of hu3S193 in patients with advanced epithelial cancers which express the Lewis-y antigen
- 15 July 2004
- journal article
- abstracts
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (14_suppl) , 2567
- https://doi.org/10.1200/jco.2004.22.14_suppl.2567
Abstract
2567 Background: The Lewis-y (Ley) antigen is a blood group related antigen that is expressed in a high proportion of epithelial cancers. We have generated a humanised antibody (hu3S193) against Ley, which has potent immune effector function, and efficacy in murine tumour models (Scott et al, Cancer Res 60: 3254–3261, 2000). Methods: An open label dose escalation Phase I trial of hu3S193 in patients (pts) with advanced Ley positive epithelial cancers has been conducted. Inclusion criteria included +ve Ley expression in tumour assessed prior to study entry. Pts received 4 infusions of hu3S193 at weekly intervals, with four dose levels (5, 10, 20 and 40 mg/m2). The first infusion of hu3S193 was trace labelled with 111In to evaluate targeting. Biodistribution, pharmacokinetics, and immune response were evaluated in all patients. Results: A total of 12 pts (6M:6F; age range 42–76 yrs; 5 breast, 7 colorectal cancer) have been accrued into the study, completing the 5 (3 pts), 10 (6 pts) and 20 (3 pts) mg/m2 dos...Keywords
This publication has 0 references indexed in Scilit: